An electrochemiluminescent (ECL) assay was developed to identify compounds that inhibit the interaction of granulocyte colony-stimulating factor (GCSF) with its recombinant human receptor. The ECL technology uses a tris-(bipyridine) chelate of ruthenium, which, in the presence of excess tripropylamine, undergoes a redox reaction cycle to produce light. Paramagnetic beads with primary antibody were coated with secondary anti-GCSF receptor antibody, which were then bound with GCSF receptor. These samples were incubated with ruthenylated GCSF in the presence and absence of test compounds. The bead density, receptor and ligand concentrations, and incubation time were optimized in the assay. A set of mixed compound plates was screened to examine the feasibility of using this technology in high throughput screening. The results from this format were found to be comparable to the assay performed using a time-resolved fluorescence format.
References
1.
Morstyn, G., Burgess, A.W. (1988). Hemopoietic growth factors: A review. Cancer Res.48:5624-5637.
2.
Layton, J.E. (1992). Granulocyte colony-stimulating factor: Structure, function and physiology. Growth Factors6:179-186.
Horan, T., Wen, J., Narhi, L., Parker, V., Garcia, A., Arakawa, T., Philo, J. (1996). Dimerization of the extracellular domain of granulocyte-colony stimulating factor receptor by ligand binding: A monovalent ligand induced 2:2 complexes. Biochemistry35:4886-4896.
